Clinical trials: Diabetes Type 2
Diabetes Mellitus, Type 2
Response To Oral Agents in Diabetes (ROAD)- Pilot Study
This proposal is to fund a pilot study to assess feasibility and refine methodology for an intended large Scotland wide study on Response to Oral Agents in Diabetes (ROAD).
- Trial name
- ROAD (NCT00780715)
- Testing
- Gliclazide MR, Sitagliptin, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University of Dundee
Diabetes Mellitus Type 2
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open, dose-escalating study of PF-07081532 in patients with Type 2 diabetes on metformin (Parts A and C).
- Trial name
- NCT04305587
- Testing
- PF-07081532, Clopidogrel
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes, Sleep Disordered Breathing
Impact of Exenatide on Sleep in Type 2 Diabetes
The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment in patients with type 2 diabetes results in improved sleep duration and quality and to explore the relationship between improvements in…
- Trial name
- NCT01136798
- Testing
- Exenatide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Chicago
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.
- Trial name
- NCT01702298
- Testing
- Sitagliptin 100 mg/simvastatin 40 mg FDC, Metformin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes
This study will compare Dulce Digital (i.e., the investigators' proven-effective combination of "one-size-fits-all" educational text messages and nurse monitoring of patient-transmitted blood glucose values) and Dulce Digital-Me…
- Trial name
- DD-Me (NCT03130699)
- Testing
- Dulce Digital, Dulce Digital-Me (Automated Delivery), Dulce Digital-Me (Medical Assistant)
- Where
- 2 sites in United States
- Volunteers
- 310 people
- Sponsor
- Scripps Whittier Diabetes Institute
Diabetes Mellitus, Type 2
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.
- Trial name
- NCT00391027
- Testing
- Insulin Glargine (Lantus®), Inhaled Human Insulin (Exubera®)
- Where
- 62 sites in Belgium, Finland and 8 more
- Volunteers
- 261 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
- Trial name
- NCT01517373
- Testing
- PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus…
- Trial name
- NCT01826370
- Testing
- Linagliptin
- Where
- 51 sites in Philippines
- Volunteers
- 678 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
The purpose of this study is to obtain continuous glucose monitoring (CGM) data from individuals taking Welchol compared to placebo.
- Trial name
- NCT00993824
- Testing
- colesevelam HCl
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- HealthPartners Institute
Type 2 Diabetes Mellitus
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT02211261
- Testing
- PF-06293620
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
To demonstrate the bioequivalence of 500 mg and 1000 mg Glucophage tablets manufactured by BMS relative to the respective strengths of 500 mg and 1000 mg Diabex tablets marketed in Australia by Alphapharm in the fed state
- Trial name
- NCT01068730
- Testing
- metformin (Diabex), metformin (Glucophage™)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Carotid Artery Disease, Carotid Artery Stenosis
Effect of Raised CBF During CEA on Cognition in DM Patients
The purpose of this study is to determine if we can reduce the incidence of cognitive dysfunction - difficulty in performing certain pencil-paper, memory, finger dexterity and thinking type of tasks called neuropsychometric tests…
- Conditions
- Carotid Artery Disease, Carotid Artery Stenosis, Diabetes, Cognitive Dysfunction
- Trial name
- NCT00597545
- Testing
- Carotid endarterectomy, Shunt
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
- Trial name
- AM7D (NCT01023581)
- Testing
- Alogliptin, Metformin
- Where
- 201 sites in United States, Czechia and 11 more
- Volunteers
- 784 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.
Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (IR MST) formulation in adults…
- Trial name
- NCT02206607
- Testing
- PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Glucose, High Blood
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide
The goal of this study is to determine whether metabolic control centers in the brain can be activated in patients with type 2 diabetes (T2D) as compared to non-diabetic individuals.
- Conditions
- Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus)
- Trial name
- NCT03566511
- Testing
- Diazoxide
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Meredith Hawkins
Diabetes Mellitus, Type 1, Diabetes Mellitus
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Metabolic Disease
- Trial name
- NCT03345004
- Testing
- Diamyd, Vitamin D
- Where
- 18 sites in Czechia, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- Diamyd Medical AB
Diabetes Mellitus, Type 2
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled…
- Trial name
- NCT00295633
- Testing
- Saxagliptin, pioglitazone, rosiglitazone
- Where
- 133 sites in United States, Argentina and 6 more
- Volunteers
- 565 people
- Sponsor
- AstraZeneca
Type II Diabetes Mellitus
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
This is a multicenter randomized, double-blind, placebo- and active-controlled (liraglutide; Victoza®), parallel-group, clinical trial of MK-8521 in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic…
- Trial name
- NCT02492763
- Testing
- MK-8521, Liraglutide, Metformin
- Volunteers
- 176 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)
This study will evaluate the safety and tolerability of single doses of MK-0941 based on assessment of clinical and laboratory adverse experiences
- Trial name
- NCT01106287
- Testing
- MK-0941
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.